Habeichi Nada J, Tannous Cynthia, Yabluchanskiy Andriy, Altara Raffaele, Mericskay Mathias, Booz George W, Zouein Fouad A
Department of Pharmacology and Toxicology, American University of Beirut Faculty of Medicine, Beirut, Lebanon.
Department of Signaling and Cardiovascular Pathophysiology, Université Paris-Saclay, Inserm, UMR-S 1180, Châtenay-Malabry, France.
Int Rev Immunol. 2022;41(4):464-474. doi: 10.1080/08830185.2021.1961768. Epub 2021 Aug 11.
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in dramatic worldwide mortality. Along with developing vaccines, the medical profession is exploring new strategies to curb this pandemic. A better understanding of the molecular consequences of SARS-CoV-2 cellular infection could lead to more effective and safer treatments. This review discusses the potential underlying impact of SARS-CoV-2 in modulating interferon (IFN) secretion and in causing mitochondrial NAD depletion that could be directly linked to COVID-19's deadly manifestations. What is known or surmised about an imbalanced innate immune response and mitochondrial dysfunction post-SARS-CoV-2 infection, and the potential benefits of well-timed IFN treatments and NAD boosting therapies in the context of the COVID-19 pandemic are discussed.
由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的新型冠状病毒肺炎疫情已导致全球范围内的巨大死亡人数。在研发疫苗的同时，医学界正在探索遏制这一疫情的新策略。更好地了解SARS-CoV-2细胞感染的分子后果可能会带来更有效、更安全的治疗方法。本综述讨论了SARS-CoV-2在调节干扰素（IFN）分泌以及导致线粒体NAD耗竭方面的潜在影响，这些影响可能与新型冠状病毒肺炎的致命表现直接相关。文中还讨论了关于SARS-CoV-2感染后先天免疫反应失衡和线粒体功能障碍已知或推测的情况，以及在新型冠状病毒肺炎疫情背景下适时进行IFN治疗和NAD增强疗法的潜在益处。
